ANAPTYSBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ANAPTYSBIO, INC. (ANAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 290.85 thousand shares for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-09-21
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 70.66K shares, a 916.71% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 220.19K shares, a 42.15% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 127.36K shares, a 131.56% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 12.00K shares, a 34.10% decline year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 301.20K shares, a 7.23% increase from fiscal 2024.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 280.90K shares, a 69.99% decline from fiscal 2023.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 936.04K shares, a 45.12% increase from fiscal 2022.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 645.01K shares, a 119.55% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 70.66K shares derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | 290.85K shares 10-KT · filed 2026-09-21 | 418.20K shares derived: sum of 3 quarters · filed 2026-09-21 | 430.21K shares derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | 220.19K shares 10-Q · filed 2026-05-12 | 347.54K shares derived: sum of 2 quarters · filed 2026-09-21 | 359.55K shares derived: sum of 3 quarters · filed 2026-09-21 | 366.50K shares derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | 127.36K shares derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | 139.36K shares derived: sum of 2 quarters · filed 2026-09-21 | 146.31K shares derived: sum of 3 quarters · filed 2026-09-21 | 301.20K shares 10-KT · filed 2026-09-21 |
| 2025-09-30 | 12.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 18.95K shares derived: sum of 2 quarters · filed 2025-11-04 | 173.85K shares 10-Q · filed 2025-11-04 | 228.85K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 6.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 161.84K shares 10-Q · filed 2025-08-06 | 216.84K shares derived: sum of 3 quarters · filed 2025-08-06 | 235.06K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 154.89K shares 10-Q · filed 2025-05-05 | 209.89K shares derived: sum of 2 quarters · filed 2025-05-05 | 228.11K shares derived: sum of 3 quarters · filed 2025-05-05 | 362.19K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 55.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 73.21K shares derived: sum of 2 quarters · filed 2025-02-27 | 207.30K shares derived: sum of 3 quarters · filed 2025-02-27 | 280.90K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 18.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 152.30K shares derived: sum of 2 quarters · filed 2024-11-05 | 225.90K shares 10-Q · filed 2024-11-05 | 249.24K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 134.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 207.69K shares 10-Q · filed 2024-08-05 | 231.03K shares derived: sum of 3 quarters · filed 2024-08-05 | 324.67K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 73.61K shares 10-Q · filed 2024-05-09 | 96.95K shares derived: sum of 2 quarters · filed 2024-05-09 | 190.59K shares derived: sum of 3 quarters · filed 2024-05-09 | 585.41K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 23.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 116.98K shares derived: sum of 2 quarters · filed 2024-03-11 | 511.80K shares derived: sum of 3 quarters · filed 2024-03-11 | 936.04K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 93.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 488.46K shares derived: sum of 2 quarters · filed 2023-11-02 | 912.70K shares 10-Q · filed 2023-11-02 | 1.16M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 394.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 819.06K shares 10-Q · filed 2023-08-07 | 1.06M shares derived: sum of 3 quarters · filed 2023-08-07 | 1.16M shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 424.24K shares 10-Q · filed 2023-05-11 | 666.84K shares derived: sum of 2 quarters · filed 2023-05-11 | 762.10K shares derived: sum of 3 quarters · filed 2023-05-11 | 958.38K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 242.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 337.86K shares derived: sum of 2 quarters · filed 2023-03-01 | 534.14K shares derived: sum of 3 quarters · filed 2023-03-01 | 645.01K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 95.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 291.54K shares derived: sum of 2 quarters · filed 2022-11-08 | 402.41K shares 10-Q · filed 2022-11-08 | 479.88K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 196.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 307.15K shares 10-Q · filed 2022-08-08 | 384.61K shares derived: sum of 3 quarters · filed 2022-08-08 | 451.70K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 110.87K shares 10-Q · filed 2022-05-04 | 188.33K shares derived: sum of 2 quarters · filed 2022-05-04 | 255.42K shares derived: sum of 3 quarters · filed 2022-05-04 | 308.50K shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 77.47K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 144.56K shares derived: sum of 2 quarters · filed 2022-03-07 | 197.64K shares derived: sum of 3 quarters · filed 2022-03-07 | 293.79K shares 10-K · filed 2022-03-07 |
| 2021-09-30 | 67.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 120.17K shares derived: sum of 2 quarters · filed 2021-11-04 | 216.32K shares 10-Q · filed 2021-11-04 | 240.74K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 53.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 149.23K shares 10-Q · filed 2021-08-09 | 173.65K shares derived: sum of 3 quarters · filed 2021-08-09 | 255.47K shares derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | 96.15K shares 10-Q · filed 2021-05-04 | 120.57K shares derived: sum of 2 quarters · filed 2021-05-04 | 202.38K shares derived: sum of 3 quarters · filed 2021-05-04 | 388.19K shares derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 24.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 106.23K shares derived: sum of 2 quarters · filed 2021-02-25 | 292.04K shares derived: sum of 3 quarters · filed 2021-02-25 | 558.51K shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 81.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 267.63K shares derived: sum of 2 quarters · filed 2020-11-04 | 534.10K shares 10-Q · filed 2020-11-04 | 680.58K shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | 185.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 452.28K shares 10-Q · filed 2020-08-10 | 598.76K shares derived: sum of 3 quarters · filed 2020-08-10 | 783.39K shares derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | 266.47K shares 10-Q · filed 2020-05-06 | 412.95K shares derived: sum of 2 quarters · filed 2020-05-06 | 597.58K shares derived: sum of 3 quarters · filed 2020-05-06 | 615.96K shares derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | 146.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | 331.12K shares derived: sum of 2 quarters · filed 2020-03-02 | 349.49K shares derived: sum of 3 quarters · filed 2020-03-02 | 388.23K shares 10-K · filed 2020-03-02 |
| 2019-09-30 | 184.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | 203.01K shares derived: sum of 2 quarters · filed 2019-11-08 | 241.75K shares 10-Q · filed 2019-11-08 | 253.63K shares derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | 18.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 57.12K shares 10-Q · filed 2019-08-08 | 68.99K shares derived: sum of 3 quarters · filed 2019-08-08 | 90.73K shares derived: sum of 4 quarters · filed 2019-08-08 |
| 2019-03-31 | 38.74K shares 10-Q · filed 2019-05-07 | 50.62K shares derived: sum of 2 quarters · filed 2019-05-07 | 72.35K shares derived: sum of 3 quarters · filed 2019-05-07 | 73.35K shares derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-12-31 | 11.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | 33.61K shares derived: sum of 2 quarters · filed 2019-02-28 | 34.61K shares derived: sum of 3 quarters · filed 2019-02-28 | 58.40K shares 10-K · filed 2019-02-28 |
| 2018-09-30 | 21.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 22.74K shares derived: sum of 2 quarters · filed 2018-11-08 | 46.52K shares 10-Q · filed 2018-11-08 | 96.36K shares derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | 1.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 24.78K shares 10-Q · filed 2018-08-07 | 74.63K shares derived: sum of 3 quarters · filed 2018-08-07 | 296.01K shares derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | 23.78K shares 10-Q · filed 2018-05-08 | 73.63K shares derived: sum of 2 quarters · filed 2018-05-08 | 295.01K shares derived: sum of 3 quarters · filed 2018-05-08 | 364.10K shares derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | 49.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | 271.23K shares derived: sum of 2 quarters · filed 2018-03-05 | 340.32K shares derived: sum of 3 quarters · filed 2018-03-05 | 354.14K shares 10-K · filed 2018-03-05 |
| 2017-09-30 | 221.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 290.47K shares derived: sum of 2 quarters · filed 2017-11-07 | 304.30K shares 10-Q · filed 2017-11-07 | |
| 2017-06-30 | 69.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | 82.91K shares 10-Q · filed 2017-08-10 | ||
| 2017-03-31 | 13.82K shares 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |